A feasibility study linking the NHS England National Cancer PROM’s to the National Bowel Cancer Audit (NBOCA) data to establish the feasibility of the PROMs as part of the national clinical audit. This was assessed according to: the characteristics of
Evidence-based recommendations on alectinib (Alecensa) for untreated anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer in adults. Alectinib is recommended, within its marketing authorisation, as an option for untreated anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer (NSCLC) in adults.
Evidence-based recommendations on lenvatinib (Lenvima) and sorafenib (Nexavar) for progressive, locally advanced or metastatic differentiated thyroid cancer in adults who have had radioactive iodine. Lenvatinib and sorafenib are recommended as options for treating progressive, locally advanced or metastatic differentiated thyroid
This letter, sent to Professor Stephen Powis, provides information about the re-examination of the commissioning treatment criteria for the use of ibrutinib in previously treated patients with chronic lymphocytic leukaemia (CLL).
The findings in this report relate to the quality assurance (QA) visit of West London Bowel Cancer Screening Programme held on 2 November 2017. Finds the West London bowel cancer screening programme is well supported by the director of screening
The findings in this report relate to the quality assurance visit of the Norfolk and Norwich screening service held on 15 November 2017. Finds this well-led and resilient bowel screening team is at the forefront of bowel screening in England. The enthusiastic
Report that finds for patient experience overall ratings continue to improve, with year on year increases in reported positive experience. Patients also reported more positively on areas including involvement in decisions about care and treatment, and being treated with dignity
This report sets out baseline activity data from January to March 2017 for Stratified Follow Up and Recovery Package interventions. This is the first time national data of this type has been reported.
Evidence-based recommendations on pembrolizumab (Keytruda) for untreated PD-L1-positive metastatic non-small-cell lung cancer in adults. This guidance replaces NICE technology appraisal guidance 447.
This guideline covers diagnosing and managing early and locally advanced breast cancer. It aims to help healthcare professionals offer the right treatments to people, taking into account the person’s individual preferences. NICE has also produced guidelines on advanced breast cancer, familial breast
Evaluates the quality of care provided to women aged 70 years or older by breast cancer services in England and Wales. The aim of the audit is to evaluate the care delivered to women from the point of initial diagnosis to
Cancer UK report that notes that every year around 360,000 people in the UK were diagnosed with cancer in 2015. 36% of these people were 75 and over. By 2035, this proportion will rise to almost half (46%), because of the